JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

3.14 -2.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.06

Максимум

3.17

Ключови измерители
By Trading Economics
Приходи	1.3M -3M
Продажби	100K 100K
Марж на печалбата	-2,954
Служители	21

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-15M 24M
Предишно отваряне	5.62
Предишно затваряне	3.14

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 23:08 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 23:07 ч. UTC

Печалби

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:20 ч. UTC

Печалби

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise After Gains on Wall Street -- Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 23:47 ч. UTC

Пазарно говорене

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30.04.2026 г., 23:27 ч. UTC

Пазарно говорене

Liontown Lithium Recovery Expected to Improve -- Market Talk

30.04.2026 г., 23:22 ч. UTC

Печалби

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30.04.2026 г., 22:52 ч. UTC

Печалби

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30.04.2026 г., 22:33 ч. UTC

Печалби

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30.04.2026 г., 22:32 ч. UTC

Печалби

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30.04.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30.04.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.04.2026 г., 22:11 ч. UTC

Пазарно говорене

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30.04.2026 г., 22:05 ч. UTC

Печалби

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30.04.2026 г., 21:57 ч. UTC

Печалби

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30.04.2026 г., 21:56 ч. UTC

Печалби

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30.04.2026 г., 21:55 ч. UTC

Печалби

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30.04.2026 г., 21:54 ч. UTC

Печалби

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30.04.2026 г., 21:53 ч. UTC

Печалби

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30.04.2026 г., 21:49 ч. UTC

Печалби

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Печалба преди облагане с данъци

Продажби

Оперативна печалба

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.